Recurrent BRAF mutations in Langerhans cell histiocytosis.

By G. Badalian‐Very, J. Vergilio, B. Degar, L. Macconaill, Barbara Brandner, M. Calicchio, Frank C. Kuo, A. Ligon, K. Stevenson, Sarah M. Kehoe and 5 more. Blood, 2010

1,163 citations recorded by the source corpus.

Subfields: Immunology, Physiology, Surgery

View Paper: https://www.semanticscholar.org/paper/c5ed358afc58bfb9b9ac9adcffaee426684db754

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Donadieu
2. G. Janka
3. R. Egeler
4. I. Astigarraga
5. M. Minkov
6. V. Nanduri
7. E. Schäfer
8. C. Rodríguez-Galindo

Citations in the corpus

• Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations (2015, neutral): “The most common disease types were colorectal cancer (37 patients), non–small-cell lung cancer (20), Erdheim–Chester disease or Langerhans’-cell histiocytosis (18), primary brain tumors (13), cholangiocarcinoma (8), anaplastic thyroid cancer (7), and multiple myeloma (5).”
• Langerhans Cell Histiocytosis (LCH): Guidelines for Diagnosis, Clinical Work-Up, and Treatment for Patients Till the Age of 18 Years (2012, positive): “[53], reported somatic mutations of the BRAF oncogene in about half of the LCH patients in their series, and this finding was recently confirmed by other teams [54,55].”